Q-omics provides the consensus-scored PALLD profile across patient tissues and cancer cell-line models. PALLD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PALLD is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PALLD protein abundance shows 28,172 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where PALLD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PALLD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PALLD survival associations across molecular data types. PALLD RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PALLD RNA expression–survival associations across cancer types. High PALLD expression shows unfavorable associations in MESO, BLCA, LGG and UVM, but favorable associations in UCEC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PALLD RNA expression.
This table summarizes PALLD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PALLD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PALLD shows lower tumor expression in BLCA, KIRC, KICH and THCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher PALLD RNA expression in tumor versus normal tissue (log2 FC = +0.936, t-test p < 0.001).
This table shows molecular features associated with PALLD in patient tissues and cancer cell lines. In patient samples, PALLD shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PALLD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
